Blood culture contamination: a randomized trial evaluating the comparative effectiveness of 3 skin antiseptic interventions

Laraine L Washer,Carol Chenoweth,Hae-Won Kim,Mary A M Rogers,Anurag N Malani,James Riddell 4th,Latoya Kuhn,Bernard Noeyack Jr,Harry Neusius,Duane W Newton,Sanjay Saint,Scott A Flanders
DOI: https://doi.org/10.1086/668777
Abstract:Objective: To determine relative rates of blood culture contamination for 3 skin antisepsis interventions-10% povidone iodine aqueous solution (PI), 2% iodine tincture (IT), and 2% chlorhexidine gluconate in 70% isopropyl alcohol (CHG)-when used by dedicated phlebotomy teams to obtain peripheral blood cultures. Design: Randomized crossover trial with hospital floor as the unit of randomization. Setting: Teaching hospital with 885 beds. Patients: All adult patients undergoing peripheral blood culture collection on 3 medical-surgical floors from May 2009 through September 2009. Intervention: Each antisepsis intervention was used for 5 months on each study floor, with random crossover after a 1-month washout period. Phlebotomy teams collected all peripheral blood cultures. Each positive blood culture was adjudicated by physicians blinded to the intervention and scored as a true positive or contaminated blood culture. The primary outcome was the rate of blood culture contamination for each antisepsis agent. Results: In total, 12,904 peripheral blood culture sets were evaluated, of which 735 (5.7%) were positive. There were 98 contaminated cultures, representing 13.3% of all positive cultures. The overall blood culture contamination rate for the study population was 0.76%. Intent-to-treat rates of contaminated blood cultures were not significantly different among the 3 antiseptics ([Formula: see text]), yielding 0.58% with PI (95% confidence interval [CI], 0.38%-0.86%), 0.76% with IT (95% CI, 0.52%-1.07%), and 0.93% with CHG (95% CI, 0.67%-1.27%). Conclusion: Choice of antiseptic agent does not impact contamination rates when blood cultures are obtained by a phlebotomy team and should, therefore, be based on costs or preference. Trial registration: ClinicalTrials.gov identifier: NCT01216761 .
What problem does this paper attempt to address?